Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Swiss PharmaCan Innovation AG currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This workload is handled by 1 distinct examiner and 1 distinct art unit, indicating a focused entry into the patent prosecution process. The Biotechnology & Pharmaceuticals area is known for rigorous examination, and this single matter represents the company's current active engagement with the patent office.
The busiest examiner for this portfolio is SONG, JIANFENG, who is responsible for 1 pending. As the sole examiner currently reviewing the company's work, the progression of the application is tied to the specific examination style and technical interpretations of this individual. This concentration simplifies the prosecution strategy by requiring the applicant to address only one set of examiner concerns in the Biotechnology & Pharmaceuticals sector.
With 1 pending office action, the company can dedicate its full attention to the specific issues raised in the current round of examination. The use of 1 distinct art unit suggests that the technology is categorized within a specific pharmaceutical or biotechnological field. Practitioners should analyze the specific feedback from SONG, JIANFENG to determine the most effective path toward allowance for this identified application.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SONG, JIANFENG | 1 | 56.4% | +32.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998188 | SOLID SOLUTION MADE FROM GUM ARABIC AND AT LEAST ONE LIPOSOLUBLE ACTIVE SUBSTANCE | SONG, JIANFENG | 132d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998188 | SOLID SOLUTION MADE FROM GUM ARABIC AND AT LEAST ONE LIPOSOLUBLE ACTIVE SUBSTANCE | SONG, JIANFENG | 132d overdue |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17998188 | SOLID SOLUTION MADE FROM GUM ARABIC AND AT LEAST ONE LIPOSOLUBLE ACTIVE SUBSTANCE | SONG, JIANFENG | 1613 | §102§103 | Final Rejection | 132d overdue | Pending | Nov 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSwiss PharmaCan Innovation AG has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Jianfeng Song has the most, with 1 of Swiss PharmaCan Innovation AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.